United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24), simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. ezetimibe and simvastatin tablets are indicated for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non-high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. ezetimibe and simvastatin tablets are indicated for the reduction of elevated total-c and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24), simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. ezetimibe and simvastatin tablets are indicated for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non-high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. ezetimibe and simvastatin tablets are indicated for the reduction of elevated total-c and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments

United States - English - NLM (National Library of Medicine)

golden state medical supply - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24), simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. ezetimibe and simvastatin tablets are indicated for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non-high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. ezetimibe and simvastatin tablets are indicated for the reduction of elevated total-c and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments (e.g., ldl apheresis) or if such treatments are unavailable. no incremental benefit of ezetimibe and simvastatin tablets on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established. ezetimibe and simvastatin tablets have not been studied in fredrickson type i, iii, iv, and v dyslipidemias. ezetimibe and simvastatin tablets are contraindicated in the following conditions: - concomitant administration of strong cyp3a4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, hiv protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistat-containing products) [ see warnings and precautions ( 5.1) ]. - concomitant administration of gemfibrozil, cyclosporine, or danazol [ see warnings and precautions ( 5.1) ]. - hypersensitivity to any component of this medication [ see adverse reactions ( 6.2) ]. - active liver disease or unexplained persistent elevations in hepatic transaminase levels [ see warnings and precautions ( 5.2) ]. - women who are pregnant or may become pregnant. serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. because hmg-coa reductase inhibitors (statins), such as simvastatin, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, ezetimibe and simvastatin tablets may cause fetal harm when administered to a pregnant woman. atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. there are no adequate and well-controlled studies of ezetimibe and simvastatin tablet use during pregnancy; however, in rare reports congenital anomalies were observed following intrauterine exposure to statins. in rat and rabbit animal reproduction studies, simvastatin revealed no evidence of teratogenicity. ezetimibe and simvastatin tablets should be administered to women of childbearing age only when such patients are highly unlikely to conceive. if the patient becomes pregnant while taking this drug, ezetimibe and simvastatin tablets should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus [ see use in specific populations ( 8.1) ]. - nursing mothers. it is not known whether simvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. because statins have the potential for serious adverse reactions in nursing infants, women who require ezetimibe and simvastatin tablet treatment should not breastfeed their infants [ see use in specific populations ( 8.3) ]. terotogenic effects pregnancy category x. [ see contraindications ( 4). ] ezetimibe and simvastatin tablets ezetimibe and simvastatin tablets are contraindicated in women who are or may become pregnant. lipid-lowering drugs offer no benefit during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy. there are no adequate and well-controlled studies of ezetimibe and simvastatin tablet use during pregnancy; however, there are rare reports of congenital anomalies in infants exposed to statins in utero . animal reproduction studies of simvastatin in rats and rabbits showed no evidence of teratogenicity. serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. because statins, such as simvastatin, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, ezetimibe and simvastatin tablets may cause fetal harm when administered to a pregnant woman. if ezetimibe and simvastatin tablets are used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. women of childbearing potential, who require ezetimibe and simvastatin tablet treatment for a lipid disorder, should be advised to use effective contraception. for women trying to conceive, discontinuation of ezetimibe and simvastatin tablets should be considered. if pregnancy occurs, ezetimibe and simvastatin tablets should be immediately discontinued. ezetimibe in oral (gavage) embryo-fetal development studies of ezetimibe conducted in rats and rabbits during organogenesis, there was no evidence of embryolethal effects at the doses tested (250, 500, 1000 mg/kg/day). in rats, increased incidences of common fetal skeletal findings (extra pair of thoracic ribs, unossified cervical vertebral centra, shortened ribs) were observed at 1000 mg/kg/day (~ 10 times the human exposure at 10 mg daily based on auc 0-24hr for total ezetimibe). in rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on auc 0-24hr for total ezetimibe). ezetimibe crossed the placenta when pregnant rats and rabbits were given multiple oral doses. multiple-dose studies of ezetimibe coadministered with statins in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. reproductive findings occur at lower doses in coadministration therapy compared to monotherapy. simvastatin simvastatin was not teratogenic in rats or rabbits at doses (25, 10 mg/kg/day, respectively) that resulted in 3 times the human exposure based on mg/m 2 surface area. however, in studies with another structurally-related statin, skeletal malformations were observed in rats and mice. there are rare reports of congenital anomalies following intrauterine exposure to statins. in a review 1 of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or another structurally-related statin, the incidences of congenital anomalies, spontaneous abortions and fetal deaths/stillbirths did not exceed what would be expected in the general population. the number of cases is adequate only to exclude a 3 to 4 fold increase in congenital anomalies over the background incidence. in 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. 1 manson, j.m., freyssinges, c., ducrocq, m.b., stephenson, w.p., postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy, reproductive toxicology , 10(6):439-446, 1996. it is not known whether simvastatin is excreted in human milk. because a small amount of another drug in this class is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women taking simvastatin should not nurse their infants. a decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother [ see contraindications ( 4) ]. in rat studies, exposure to ezetimibe in nursing pups was up to half of that observed in maternal plasma. it is not known whether ezetimibe or simvastatin are excreted into human breast milk. because a small amount of another drug in the same class as simvastatin is excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women who are nursing should not take ezetimibe and simvastatin tablets [ see contraindications ( 4) ]. the effects of ezetimibe coadministered with simvastatin (n = 126) compared to simvastatin monotherapy (n = 122) have been evaluated in adolescent boys and girls with heterozygous familial hypercholesterolemia (hefh). in a multicenter, double-blind, controlled study followed by an open-label phase, 142 boys and 106 postmenarchal girls, 10 to 17 years of age (mean age 14.2 years, 43% females, 82% caucasians, 4% asian, 2% blacks, 13% multiracial) with hefh were randomized to receive either ezetimibe coadministered with simvastatin or simvastatin monotherapy. inclusion in the study required 1) a baseline ldl-c level between 160 and 400 mg/dl and 2) a medical history and clinical presentation consistent with hefh. the mean baseline ldl-c value was 225 mg/dl (range: 161 to 351 mg/dl) in the ezetimibe coadministered with simvastatin group compared to 219 mg/dl (range: 149 to 336 mg/dl) in the simvastatin monotherapy group. the patients received coadministered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) or simvastatin monotherapy (10 mg, 20 mg, or 40 mg) for 6 weeks, coadministered ezetimibe and 40 mg simvastatin or 40 mg simvastatin monotherapy for the next 27 weeks, and open-label coadministered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter. the results of the study at week 6 are summarized in table 3 . results at week 33 were consistent with those at week 6. total-c ldl-c apo b non-hdl-c tg 1 hdl-c mean percent difference between treatment groups -12% -15% -12% -14% -2% +0.1% 95% confidence interval (-15%, -9%) (-18%, -12%) (-15%, -9%) (-17%, -11%) (-9, +4) (-3, +3) 1.  for triglycerides, median % change from baseline. from the start of the trial to the end of week 33, discontinuations due to an adverse reaction occurred in 7 (6%) patients in the ezetimibe coadministered with simvastatin group and in 2 (2%) patients in the simvastatin monotherapy group. during the trial, hepatic transaminase elevations (two consecutive measurements for alt and/or ast ≥ 3 x uln) occurred in four (3%) individuals in the ezetimibe coadministered with simvastatin group and in two (2%) individuals in the simvastatin monotherapy group. elevations of cpk (≥ 10 x uln) occurred in two (2%) individuals in the ezetimibe coadministered with simvastatin group and in zero individuals in the simvastatin monotherapy group. in this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on menstrual cycle length in girls. coadministration of ezetimibe with simvastatin at doses greater than 40 mg/day has not been studied in adolescents. also, ezetimibe and simvastatin tablets have not been studied in patients younger than 10 years of age or in pre-menarchal girls. ezetimibe based on total ezetimibe (ezetimibe + ezetimibe-glucuronide) there are no pharmacokinetic differences between adolescents and adults. pharmacokinetic data in the pediatric population < 10 years of age are not available. simvastatin the pharmacokinetics of simvastatin has not been studied in the pediatric population. of the 10,189 patients who received ezetimibe and simvastatin tablets in clinical studies, 3,242 (32%) were 65 and older (this included 844 (8%) who were 75 and older). no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients but greater sensitivity of some older individuals cannot be ruled out. since advanced age (≥ 65 years) is a predisposing factor for myopathy, ezetimibe and simvastatin tablets should be prescribed with caution in the elderly [ see clinical pharmacology ( 12.3) ]. because advanced age (≥ 65 years) is a predisposing factor for myopathy, including rhabdomyolysis, ezetimibe and simvastatin tablets should be prescribed with caution in the elderly. in a clinical trial of patients treated with simvastatin 80 mg/day, patients ≥ 65 years of age had an increased risk of myopathy, including rhabdomyolysis, compared to patients < 65 years of age [ see warnings and precautions ( 5.1) and clinical pharmacology ( 12.3) ]. in the sharp trial of 9,270 patients with moderate to severe renal impairment (6,247 non-dialysis patients with median serum creatinine 2.5 mg/dl and median estimated glomerular filtration rate 25.6 ml/min/1.73 m 2 , and 3,023 dialysis patients), the incidence of serious adverse events, adverse events leading to discontinuation of study treatment, or adverse events of special interest (musculoskeletal adverse events, liver enzyme abnormalities, incident cancer) was similar between patients ever assigned to ezetimibe and simvastatin tablets, 10 mg/20 mg (n = 4,650) or placebo (n = 4,620) during a median follow-up of 4.9 years. however, because renal impairment is a risk factor for statin-associated myopathy, doses of ezetimibe and simvastatin tablets exceeding 10 mg/20 mg should be used with caution and close monitoring in patients with moderate to severe renal impairment [ see dosage and administration ( 2.5), adverse reactions ( 6.1), and clinical studies ( 14.3) ]. ezetimibe and simvastatin tablets are contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminases [ see contraindications ( 4) and warnings and precautions ( 5.2) ]. in a clinical trial in which patients at high risk of cardiovascular disease were treated with simvastatin 40 mg/day (median follow-up 3.9 years), the incidence of myopathy was approximately 0.05% for non-chinese patients (n=7367) compared with 0.24% for chinese patients (n=5468). the incidence of myopathyfor chinese patients on simvastatin 40 mg/day or ezetimibe and simvastatin 10/40 mg/day coadministered with extended-release niacin 2 g/day was 1.24%. chinese patients may be at higher risk for myopathy, monitor patients appropriately. coadministration of ezetimibe and simvastatin tablets with lipid-modifying doses (≥1 g/day niacin) of niacin-containing products is not recommended in chinese patients [see warnings and precautions (5.1), drug interactions (7.4)].

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24), simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - simvastatin simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. ezetimibe and simvastatin tablets are contraindicated in the following conditions: ezetimibe and simvastatin tablets the safety and effectiveness of ezetimibe in combination with a statin as an adjunct to diet to reduce ldl-c have been established in pediatric patients 10 years of age and older with hefh. use of ezetimibe and simvastatin tablets for this indication is based on a double-blind, placebo-controlled clinical trial in 248 pediatric patients (142 males and 106 postmenarchal females) 10 years of age and older with hefh [see clinical studies (14)]. in this limited controlled trial, there was no significant effect on growth or sexual maturation in the adolescent males or females, or on menstrual cycle length in females. the safety and effectiveness of ezetimibe and simvastatin tablets have not been established in pediatric patients younger than 10 years of age with hefh, or in pediatric patients with other types of hyperlipidemia. in a clinical trial in which patients at high risk of cvd were treated with simvastatin 40 mg/day (median follow-up 3.9 years), the incidence of myopathy was approximately 0.05% for non-chinese patients (n=7367) compared with 0.24% for chinese patients (n=5468). in this trial the incidence of myopathy for chinese patients on simvastatin 40 mg/day or ezetimibe and simvastatin 10/40 mg/day coadministered with extended-release niacin 2 g/day was 1.24%. chinese patients may be at higher risk for myopathy, monitor these patients appropriately. coadministration of ezetimibe and simvastatin tablets with lipid-modifying doses of niacin-containing products (≥1 g/day niacin) is not recommended in chinese patients [see warnings and precautions ( 5.1) and drug interactions ( 7.1 )] .

United States - English - NLM (National Library of Medicine)

northstar rx llc - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24), simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - ezetimibe and simvastatin tablets are contraindicated in the following conditions: pregnancy category x. ezetimibe and simvastatin tablets ezetimibe simvastatin simvastatin was not teratogenic in rats or rabbits at doses (25, 10 mg/kg/day, respectively) that resulted in 3 times the human exposure based on mg/m2 surface area. however, in studies with another structurally-related statin, skeletal malformations were observed in rats and mice. there are rare reports of congenital anomalies following intrauterine exposure to statins. in a review1 of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or another structurally-related statin, the incidences of congenital anomalies, spontaneous abortions and fetal deaths/stillbirths did not exceed what would be expected in the general population. the number of cases is adequate only to exclude a 3- to 4-fold increase in congenital anomalies over the background incidence. in 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. the effects of ezetimibe coadministered with simvastatin (n=126) compared to simvastatin monotherapy (n=122) have been evaluated in adolescent boys and girls with heterozygous familial hypercholesterolemia (hefh). in a multicenter, double-blind, controlled study followed by an open-label phase, 142 boys and 106 postmenarchal girls, 10 to 17 years of age (mean age 14.2 years, 43% females, 82% caucasians, 4% asian, 2% blacks, 13% multiracial) with hefh were randomized to receive either ezetimibe coadministered with simvastatin or simvastatin monotherapy. inclusion in the study required 1) a baseline ldl-c level between 160 and 400 mg/dl and 2) a medical history and clinical presentation consistent with hefh. the mean baseline ldl-c value was 225 mg/dl (range: 161 to 351 mg/dl) in the ezetimibe coadministered with simvastatin group compared to 219 mg/dl (range: 149 to 336 mg/dl) in the simvastatin monotherapy group. the patients received coadministered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) or simvastatin monotherapy (10 mg, 20 mg, or 40 mg) for 6 weeks, coadministered ezetimibe and 40 mg simvastatin or 40 mg simvastatin monotherapy for the next 27 weeks, and open-label coadministered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter. the results of the study at week 6 are summarized in table 3. results at week 33 were consistent with those at week 6. mean percent difference between treatment groups -12% -15% -12% -14% -2% +0.1% 95% confidence interval (-15%, -9%) (-18%, -12%) (-15%, -9%) (-17%, -11%) (-9, +4) (-3, +3) * for triglycerides, median % change from baseline. from the start of the trial to the end of week 33, discontinuations due to an adverse reaction occurred in 7 (6%) patients in the ezetimibe coadministered with simvastatin group and in 2 (2%) patients in the simvastatin monotherapy group. during the trial, hepatic transaminase elevations (two consecutive measurements for alt and/or ast ≥3 x uln) occurred in four (3%) individuals in the ezetimibe coadministered with simvastatin group and in two (2%) individuals in the simvastatin monotherapy group. elevations of cpk (≥10 x uln) occurred in two (2%) individuals in the ezetimibe coadministered with simvastatin group and in zero individuals in the simvastatin monotherapy group. in this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on menstrual cycle length in girls. coadministration of ezetimibe with simvastatin at doses greater than 40 mg/day has not been studied in adolescents. also, ezetimibe and simvastatin tablets have not been studied in patients younger than 10 years of age or in pre-menarchal girls. ezetimibe based on total ezetimibe (ezetimibe + ezetimibe-glucuronide) there are no pharmacokinetic differences between adolescents and adults. pharmacokinetic data in the pediatric population <10 years of age are not available. simvastatin the pharmacokinetics of simvastatin has not been studied in the pediatric population. in a clinical trial in which patients at high risk of cardiovascular disease were treated with simvastatin 40 mg/day (median follow-up 3.9 years), the incidence of myopathy was approximately 0.05% for non- chinese patients (n=7367) compared with 0.24% for chinese patients (n=5468). the incidence of myopathy for chinese patients on simvastatin 40 mg/day or ezetimibe and simvastatin 10/40 mg/day coadministered with extended-release niacin 2 g/day was 1.24%. chinese patients may be at higher risk for myopathy, monitor patients appropriately. coadministration of ezetimibe and simvastatin tablets with lipid-modifying doses (≥1 g/day niacin) of niacin-containing products is not recommended in chinese patients [see warnings and precautions (5.1), drug interactions ( error! hyperlink reference not valid. )] .

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24), simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. ezetimibe and simvastatin tablets are indicated for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non-high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. ezetimibe and simvastatin tablets are indicated for the reduction of elevated total-c and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24), simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. ezetimibe and simvastatin tablets are indicated for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non-high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia.  ezetimibe and simvastatin tablets are indicated for the reduction of elevated total-c and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments

United States - English - NLM (National Library of Medicine)

rebel distributors corp - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24), simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - ezetimibe 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. vytorin is indicated for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non-high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. vytorin is indicated for the reduction of elevated total-c and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments (e.g., ldl apheresis) or if such treatments are unavai

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24), simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - ezetimibe 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. vytorin® is indicated for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non-high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. vytorin is indicated for the reduction of elevated total-c and ldl-c in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments (e.g., ldl apheresis) or if such treatments are unav

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24), simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - ezetimibe and simvastatin tablets are contraindicated in the following conditions: pregnancy category x. ezetimibe and simvastatin tablets ezetimibe simvastatin simvastatin was not teratogenic in rats or rabbits at doses (25, 10 mg/kg/day, respectively) that resulted in 3 times the human exposure based on mg/m2 surface area. however, in studies with another structurally-related statin, skeletal malformations were observed in rats and mice. there are rare reports of congenital anomalies following intrauterine exposure to statins. in a review1 of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or another structurally-related statin, the incidences of congenital anomalies, spontaneous abortions and fetal deaths/stillbirths did not exceed what would be expected in the general population. the number of cases is adequate only to exclude a 3- to 4-fold increase in congenital anomalies over the background incidence. in 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. the effects of ezetimibe coadministered with simvastatin (n=126) compared to simvastatin monotherapy (n=122) have been evaluated in adolescent boys and girls with heterozygous familial hypercholesterolemia (hefh). in a multicenter, double-blind, controlled study followed by an open-label phase, 142 boys and 106 postmenarchal girls, 10 to 17 years of age (mean age 14.2 years, 43% females, 82% caucasians, 4% asian, 2% blacks, 13% multiracial) with hefh were randomized to receive either ezetimibe coadministered with simvastatin or simvastatin monotherapy. inclusion in the study required 1) a baseline ldl-c level between 160 and 400 mg/dl and 2) a medical history and clinical presentation consistent with hefh. the mean baseline ldl-c value was 225 mg/dl (range: 161 to 351 mg/dl) in the ezetimibe coadministered with simvastatin group compared to 219 mg/dl (range: 149 to 336 mg/dl) in the simvastatin monotherapy group. the patients received coadministered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) or simvastatin monotherapy (10 mg, 20 mg, or 40 mg) for 6 weeks, coadministered ezetimibe and 40 mg simvastatin or 40 mg simvastatin monotherapy for the next 27 weeks, and open-label coadministered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter. the results of the study at week 6 are summarized in table 3. results at week 33 were consistent with those at week 6. mean percent difference between treatment groups -12% -15% -12% -14% -2% +0.1% 95% confidence interval (-15%, -9%) (-18%, -12%) (-15%, -9%) (-17%, -11%) (-9, +4) (-3, +3) * for triglycerides, median % change from baseline. from the start of the trial to the end of week 33, discontinuations due to an adverse reaction occurred in 7 (6%) patients in the ezetimibe coadministered with simvastatin group and in 2 (2%) patients in the simvastatin monotherapy group. during the trial, hepatic transaminase elevations (two consecutive measurements for alt and/or ast ≥3 x uln) occurred in four (3%) individuals in the ezetimibe coadministered with simvastatin group and in two (2%) individuals in the simvastatin monotherapy group. elevations of cpk (≥10 x uln) occurred in two (2%) individuals in the ezetimibe coadministered with simvastatin group and in zero individuals in the simvastatin monotherapy group. in this limited controlled study, there was no significant effect on growth or sexual maturation in the adolescent boys or girls, or on menstrual cycle length in girls. coadministration of ezetimibe with simvastatin at doses greater than 40 mg/day has not been studied in adolescents. also, ezetimibe and simvastatin tablets have not been studied in patients younger than 10 years of age or in pre-menarchal girls. ezetimibe based on total ezetimibe (ezetimibe + ezetimibe-glucuronide) there are no pharmacokinetic differences between adolescents and adults. pharmacokinetic data in the pediatric population <10 years of age are not available. simvastatin the pharmacokinetics of simvastatin has not been studied in the pediatric population. in a clinical trial in which patients at high risk of cardiovascular disease were treated with simvastatin 40 mg/day (median follow-up 3.9 years), the incidence of myopathy was approximately 0.05% for non- chinese patients (n=7367) compared with 0.24% for chinese patients (n=5468). the incidence of myopathy for chinese patients on simvastatin 40 mg/day or ezetimibe and simvastatin 10/40 mg/day coadministered with extended-release niacin 2 g/day was 1.24%. chinese patients may be at higher risk for myopathy, monitor patients appropriately. coadministration of ezetimibe and simvastatin tablets with lipid-modifying doses (≥1 g/day niacin) of niacin-containing products is not recommended in chinese patients [see warnings and precautions (5.1), drug interactions ( error! hyperlink reference not valid. )] .